Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s share price was up 1.8% during trading on Friday . The stock traded as high as $9.40 and last traded at $9.37, with a volume of 51,521 shares trading hands. The stock had previously closed at $9.20.

Several equities analysts have recently commented on AQXP shares. Jefferies Group raised their price target on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the company a “hold” rating in a research note on Friday, August 5th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, July 21st. Needham & Company LLC started coverage on Aquinox Pharmaceuticals in a research note on Thursday, May 12th. They set a “buy” rating and a $25.00 price target on the stock. Finally, Zacks Investment Research lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Aquinox Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $19.86.

The firm’s 50 day moving average price is $8.25 and its 200 day moving average price is $8.44. The company’s market cap is $162.48 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.22. On average, analysts expect that Aquinox Pharmaceuticals Inc. will post ($2.08) EPS for the current year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.